Lundbeck Q3 2019 Financial Results

9M 2019: Continued strong growth from strategic brands and negative impact from generic erosion on mature products as expected * Revenue: Down 9% (9% in L.C.) to DKK 12.6 billion I Revenue (9M - DKKm) -9% Core EBIT (9M - DKKM) -23% 14.000 5.500 Performance driven by strategic 13.000 brands mitigating effect from 5.000 12.000 EXULTI generics 4.500 11.000 10.000 Northera 4.000 Other revenue: Down 7% to 9.000 3.500 DKK 433 million Brintellix 8.000 Trintellix 3.000 7.000 Effects from hedging: Loss of Abilify Maintenc 2.500 6.000 DKK 194 million 5.000 2.000 I * Core EBIT margin: 31.8% vs. 4.000 1.500 37.5% in 9M 2018 following generic erosion of Onfi 3.000 Other pharma 1.000 2.000 500 1.000 Rest 0 0 9M.18 9M.19 9M.17 9M.18 9M.19 45 Lundbeck

View entire presentation